425: TuHURA Biosciences Secures $12.6 Million in Private Placement to Fuel Pipeline Advancement and Kineta Merger

TuHURA Biosciences, Inc. has entered into a definitive securities purchase agreement for a private placement totaling approximately $12.6 million, alongside an additional $3.0 million from prior warrant exercises, to fund its strategic merger with Kineta, Inc. and advance its oncology pipeline.

Summary

• TuHURA Biosciences, Inc. (NASDAQ:HURA) has entered into a securities purchase agreement with investors for a private placement (the "Offering") of approximately $12.6 million.
• The Offering involves the issuance of 4.76 million shares of common stock and warrants to purchase an equal number of shares at an exercise price of $3.3125 per warrant share.
• The combined effective offering price for each share and accompanying warrant was $2.65, representing a 15% discount to the NASDAQ closing price on June 2, 2025.
• The $12.6 million aggregate offering amount is structured in tranches: $2.23 million at the initial closing, and three subsequent $2.23 million tranches contingent on specific milestones.
• The milestones for subsequent tranches include the FDA lifting a partial clinical hold on the IFx-2.0 Phase 3 trial, initiation of the Phase 3 trial for IFx-Hu2.0, and satisfaction of material conditions for the Kineta, Inc. merger.
• An additional $3.7 million of the offering is required to be purchased and funded by December 31, 2025, by certain larger investors.
• The company previously secured $3.0 million in cash proceeds from the exercise of approximately 1.0 million warrants in February 2025.
• Net proceeds from the Offering and prior warrant exercises are planned for cash requirements for the Kineta merger closing, initiation of the IFx-2.0 Phase 3 Trial, advancement of KVA12123 to a Phase 2 trial, and general working capital needs.
• The company has agreed to file a registration statement for the resale of the shares and warrant shares within 60 calendar days of the initial closing and to use reasonable efforts to make it effective within 120 calendar days.
• Paulson Investment Company, LLC acted as exclusive placement agent, and Brookline Capital Markets provided equity market advisory services for the Offering.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company successfully secured significant funding crucial for its strategic merger and pipeline advancement. While the funding is contingent on milestones and there's an existing clinical hold, the capital infusion and clear strategic path forward are strong positives for a clinical-stage biotech.

Positives

• Secured approximately $12.6 million in new funding commitments, providing capital for key strategic initiatives.
• The funding is tied to critical development milestones, including the lifting of an FDA clinical hold and initiation of a Phase 3 trial, indicating investor confidence in these achievements.
• An additional $3.0 million in cash was received from previous warrant exercises, bolstering the company's financial position.
• Proceeds are earmarked to fund the proposed merger with Kineta, Inc., which will expand TuHURA's pipeline with Kineta's KVA12123 novel VISTA-inhibiting antibody for a Phase 2 trial in NPM1 Mutated r/r AML.
• The funding supports the initiation of the planned Phase 3 accelerated approval trial for IFx-2.0 in Merkel Cell Carcinoma, a significant step towards potential market approval.
• The company is also advancing its first-in-class immune modulating bi-specific, and bi-functional Antibody Drug Conjugates (ADC) and Antibody Peptide Conjugates (APCs) programs.

Negatives

• A significant portion of the funding ($10.38 million) is contingent upon the achievement of specific milestones, including the lifting of an FDA partial clinical hold and the initiation of a Phase 3 trial, introducing funding uncertainty.
• The company is currently subject to a partial clinical hold on its planned Phase 3 trial of IFx-2.0, which must be lifted to unlock a tranche of funding.
• The combined offering price of $2.65 per share and accompanying warrant represents a 15% discount to the NASDAQ closing price on June 2, 2025, indicating dilution for existing shareholders.

Risks

• The company's ability to receive the full $10.38 million in additional gross proceeds is contingent on the satisfaction of specific funding milestones, including regulatory approvals and trial initiations.
• There is a partial clinical hold set forth in the FDA's letter dated January 24, 2024, with respect to the company's planned Phase 3 trial of IFx-2.0, which could delay funding and program advancement.
• The completion of the proposed merger with Kineta, Inc. is subject to material conditions that must be satisfied, and failure to do so would impact funding and strategic plans.
• The company's need for additional capital, including financing to complete the Kineta merger, is a forward-looking statement and actual capital resources may differ.
• The anticipated regulatory pathway and timing of development programs, studies, and trials are subject to change and may not proceed as expected.
• Actual results or developments may differ materially from forward-looking statements due to various factors described in SEC filings.

Future Outlook

TuHURA Biosciences anticipates that the proceeds from the current offering and prior warrant exercises will be sufficient to fund its cash needs for the completion of the proposed merger with Kineta, Inc., contingent on the satisfaction of funding milestones and other closing conditions. The company plans to use these funds to initiate the Phase 3 trial for IFx-2.0, advance Kineta's KVA12123 to a Phase 2 trial post-merger, and support other working capital needs. The company expects all funding milestones to be achieved by the end of July 2025.

Management Comments

• The Company currently expects that the proceeds from the offering, in addition to the cash proceeds from the warrant exercises, will be sufficient to fund the Company's cash needs for completion of the Company's proposed merger with Kineta, Inc. contingent on the satisfaction of the Funding Milestones and the satisfaction of all other closing conditions and requirements relating to the completion of the merger.

Industry Context

This announcement positions TuHURA Biosciences as an active player in the immuno-oncology space, particularly in addressing resistance to cancer immunotherapy. The strategic private placement and proposed merger with Kineta, Inc. reflect a trend towards consolidation and pipeline expansion within the biotech industry, especially for companies with promising clinical-stage assets. The focus on overcoming primary and acquired resistance, and targeting specific mechanisms like VISTA inhibition and Myeloid Derived Suppressor Cells, aligns with cutting-edge research in cancer treatment, aiming to improve patient response rates to existing checkpoint inhibitors and cellular therapies.

Comparison to Industry Standards

• The private placement structure, with tranches tied to clinical and corporate milestones, is a common financing mechanism for clinical-stage biotech companies, allowing investors to de-risk their investment as development progresses. This is similar to financing rounds seen in companies like <Company A> or <Company B> that are advancing assets through pivotal trials.
• The 15% discount on the combined offering price relative to the market price is within the typical range for private placements in the biotech sector, where discounts are often necessary to attract institutional investors given the inherent risks.
• The mention of a partial clinical hold by the FDA on IFx-2.0's Phase 3 trial is a significant regulatory hurdle, comparable to challenges faced by other oncology developers such as <Company C>'s recent trial suspension for <Drug X> or <Company D>'s delays in <Trial Y> due to safety concerns. The ability to resolve this hold is critical and will be closely watched by the market.
• The proposed merger with Kineta, Inc. to acquire KVA12123, a VISTA-inhibiting antibody, reflects a strategic move to diversify and strengthen the pipeline. This mirrors similar M&A activities in the oncology sector, such as <Company E>'s acquisition of <Company F> for its novel immunotherapy platform, where companies seek to gain synergistic assets and expand market reach.
• Advancing a VISTA-inhibiting antibody (KVA12123) to a Phase 2 trial in NPM1 Mutated r/r AML is a notable step, as VISTA is an emerging immune checkpoint target. This positions TuHURA alongside other companies exploring novel checkpoints beyond PD-1/L1, such as <Company G> with its TIGIT inhibitor or <Company H> with its LAG-3 program, aiming to address unmet needs in difficult-to-treat cancers.

Stakeholder Impact

• **Shareholders**: Potential for dilution from the new share issuance and warrant exercise, but also benefit from strengthened financial position, pipeline advancement, and strategic merger, which could drive long-term value.
• **Employees**: Increased job security and potential for growth opportunities due to continued funding for R&D and the expansion through the Kineta merger.
• **Customers (Future Patients)**: Potential for new treatment options if clinical trials are successful and lead to approved therapies for cancer.
• **Creditors**: Improved financial stability and liquidity, potentially reducing credit risk.
• **Suppliers/Partners**: Continued and potentially increased business opportunities as R&D activities and clinical trials progress.

Next Steps

• Receive notification from the FDA that the partial clinical hold on IFx-2.0 Phase 3 trial is lifted.
• Initiate the Phase 3 trial for IFx-Hu2.0.
• Satisfy all material conditions for the closing of the proposed merger transaction with Kineta, Inc.
• Advance Kineta's KVA12123 novel VISTA-inhibiting antibody to a Phase 2 trial post-merger.
• File a registration statement for the resale of the shares and shares underlying the warrants no later than 60 calendar days following the initial closing.
• Use reasonable efforts to cause the resale registration statement to become effective within 120 calendar days following the initial closing.
• Certain purchasers to fund the remaining $3.7 million of the offering by December 31, 2025.

Key Dates

Recommendation

Keywords

TuHURA Biosciences, HURA, Private Placement, Equity Financing, SEC Filing, Biotechnology, Immuno-oncology, Cancer Immunotherapy, IFx-2.0, Phase 3 Trial, Clinical Hold, FDA, Kineta Merger, KVA12123, VISTA-inhibiting antibody, NPM1 Mutated AML, Antibody Drug Conjugates, Antibody Peptide Conjugates, Warrants, Common Stock, Capital Raise